China Economic Net, Beijing, January 26 Today, Bide Pharmaceutical (688073SH) stock price**, as of ** at 4470 yuan, down 840%, with a total market capitalization of 406.2 billion yuan. The stock is currently trading below the issue price.
Bide Pharma was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on October 11, 2022, with an issue of 1,62291,000,000 shares, 8800 yuan shares. The sponsor of the company is Yang Yang and Lei Hao, the sponsor representatives of Haitong ** shares.
The total amount of funds raised by the company's listing and issuance was 142,816080,000 yuan; Net proceeds after deducting issuance expenses amounted to 130,899890,000 yuan. The company ultimately raised 87,464 more net funds than originally planned280,000 yuan, according to the prospectus disclosed by the company on September 29, 2022, the company intends to raise 43,435610,000 yuan, which will be used for the regional center project of drug molecular building blocks, the R&D laboratory project, and the replenishment of working capital.
The total cost of the issuance is 11,916190,000 yuan, of which Haitong ** shares *** received underwriting and sponsorship fees of 9,283050,000 yuan.
The strategic placement of the issuance consists of the co-investment of the relevant subsidiaries of the sponsor and the special asset management plan of the senior management and core employees of the issuer. The sponsor (lead underwriter) of this offering participates in the strategic placement of this offering in accordance with the relevant provisions of the "Implementation Measures" and the "Underwriting Guidelines", and the co-investment subject is Haitong Innovation ** Investment *** The number of co-investment placement is 400%, or 649,164 shares, with an allotted amount of 57,126,43200 yuan. The senior management and core employees of the issuer participated in the special asset management plan established by the strategic placement, and the employees of Fucheng Haifutong Bide Pharma participated in the strategic placement of the Science and Technology Innovation Board, and the collective asset management plan was actually allotted 1,622,910 shares, with an allotted amount of 142,816,08000 yuan, accounting for 10 of the number of this issuance00%。
According to the announcement on the implementation of the 2022 annual equity distribution disclosed by Bide Pharma on May 19, 2023, the profit distribution and conversion of share capital are based on the company's total share capital of 64,916,392 shares before the implementation of the plan, and a cash dividend of 154 yuan (tax included), with capital reserve to all shareholders per share increased by 04 shares, a total cash dividend of 99,971,24368 yuan, an increase of 25,966,556 shares, and the total share capital after this distribution is 90,882,948 shares.